BMEA (Biomea Fusion) Moat Score: 3/10 (As of Jul. 02, 2026)


BMEA Biomea Fusion Inc BMEA
33 GF Score
Price $1.41
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Moat Score?

Biomea Fusion BMEA +3.68% 33 Moat Score is 3 as of Jul. 02, 2026. GuruFocus rates BMEA with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Biomea Fusion ranks better than 75.5% on this metric.

Biomea Fusion has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Biomea Fusion has No Moat: Biomea Fusion is in the early stages of development with no significant market leadership or intellectual property. It lacks strong brand strength, cost advantages, or regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Biomea Fusion might have No Moat - Very weak/transient advantages.

Biomea Fusion  (NAS:BMEA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Biomea Fusion Moat Score Related Terms

BMEA vs ANIX, PMN, ATRA: Moat Score Comparison

For the Biotechnology subindustry, Biomea Fusion's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Moat Score distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Moat Score falls into.


BMEA
33GF Score
Biomea Fusion Inc BMEA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Biomea Fusion (BMEA) has a Moat Score of 3 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Biomea Fusion ranks #343 out of 1400 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Biomea Fusion's Moat Score too high?
Biomea Fusion's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Biomea Fusion's value of 3 is 50% above this industry median. Based on the distribution chart, Biomea Fusion ranks #343 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biomea Fusion has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Moat Score compare to ANIX and PMN?
According to the Biotechnology industry distribution chart, Biomea Fusion ranks #343 out of 1400 companies for Moat Score. This places Biomea Fusion in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Biomea Fusion's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomea Fusion's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomea Fusion's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Biomea Fusion's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Moat Score is 3 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
33GF Score

Get the complete analysis for BMEA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.41
Price